Found: 1
Select item for more details and to access through your institution.
Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon α-2a in the treatment of chronic hepatitis C.
- Published in:
- Hepatology Research, 2008, v. 38, n. 3, p. 259, doi. 10.1111/j.1872-034X.2007.00260.x
- By:
- Publication type:
- Article